• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board

    11/20/24 11:50:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AIM alert in real time by email

    The Delaware Supreme Court Ruled that the Incumbent Board Breached its Fiduciary Duties to Stockholders

    AIM Board Wasted Millions in Furtherance of Improper Purpose

    Stockholders Urged to Act Now Before the Board's Self-Interested Behavior Irreversibly Damages the Company

    Stockholders Should Not be Fooled by Misleading Statements by AIM Board – The Facts Speak for Themselves

    Kellner Group Nominees Bring Skills, Experience and Credibility Necessary for AIM to be Successful

    NEW YORK, Nov. 14, 2024 /PRNewswire/ -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, the "Kellner Group Nominees") today issued the following statement in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE:AIM) and finally start creating value for stockholders. Mr. Kellner is convinced that the Kellner Group Nominees have the experience to make AIM successful and that an immediate change in directors on the AIM board at this year's annual meeting is absolutely necessary.

    The Delaware Supreme Court Ruled that the Incumbent Board Breached its Fiduciary Duties to Stockholders.

    On July 11, 2024, the Delaware Supreme Court ruled that bylaws adopted by the Board in 2023 were inequitable and unenforceable. The court found that the Board's motive was not to counter the threat of an uninformed vote. Rather, the "primary purpose was to interfere with Kellner's nomination notice, reject his nominees, and maintain control." The court ruled that the 2023 amended bylaws were the "product of an improper motive and purpose, which constitutes a breach of the duty of loyalty." (emphasis added)

    This illegal behavior by the AIM Board was not an isolated incident. A federal district court in Florida sanctioned AIM and its counsel in 2024 in its Section 13(d) claims against members of the Kellner Group and others – claims that have been dismissed multiple times – for pursuing arguments that were "factually and legally frivolous and advanced for an improper purpose." (emphasis added)

    The incumbent Board is engaged in what we consider to be gross waste in pursuit of its improper purpose. Based on AIM's own disclosures, we estimate that the incumbent Board has spent between $15.0 to $20.0 million in just the past two years in their bad faith effort to prevent a meaningful election of directors and maintain control. This is an unconscionable amount for a company of AIM's size – approximately equal to its entire market capitalization. We believe the incumbent Board bears sole responsibility for this waste - the incumbent directors initiated and continued this effort in order to entrench themselves and disenfranchise stockholders. And instead of raising capital to research and develop Ampligen, the Board has chosen to raise capital -- at enormous expense from unscrupulous lenders and at usurious rates -- to fund litigation against stockholders who seek to hold the Board accountable at the ballot box. As a direct result of the Board's bad faith actions, AIM's stock price is down 99+% since the incumbent Board took control and continues to reach new lows and its financial condition has significantly deteriorated to the point that its viability is in serious jeopardy.

    All of the incumbent Board members bear responsibility and must be held accountable. Although Mr. Equels, Dr. Mitchell and Mr. Appelrouth adopted the 2023 bylaw amendments in breach of their fiduciary duties, the improper purpose and waste has clearly continued in our view. Ms. Bryan joined the Board in spring of 2023 – after being hand-picked by Mr. Equels and rubber-stamped by Dr. Mitchell and Mr. Appelrouth – and has joined right in. All four incumbent Board members – Equels, Mitchell, Appelrouth and Bryan – should be held responsible for spending millions to disenfranchise stockholders last year and continuing to pursue improper litigation. Ms. Bryan is the chair of the compensation committee that recently signed off on the issuance of almost 900,000 shares of fully vested common stock to Mr. Equels and Mr. Rodino, AIM's COO and General Counsel, as an advance on salary payable in the next year. We believe that doing this before the record date for this year's annual meeting, with the knowledge that AIM was facing another proxy contest, clearly demonstrates continuation of the same bad faith entrenchment efforts from the incumbent Board.

    The incumbent Board's claim that it is taking these wasteful and self-interested actions to protect stockholders is disingenuous and lacks credibility in our view. AIM's stockholders have clearly, and repeatedly, conveyed a clear message to the Board that they demand change. This was evident in the significant support of stockholders for the election of Mr. Kellner, Mr. Deutsch and Mr. Chioini at the 2023 annual meeting of stockholders, and the significant support for the election of Mr. Chioini and another nominee at the 2022 annual meeting of stockholders. It was evident in the overwhelming failures of the say-on-pay votes at the last three annual meetings of stockholders.

    The incumbent Board has acknowledged this stockholder dissatisfaction – two years ago, after the 2022 annual meeting, AIM announced that it valued stockholder feedback and would seek to add two new independent directors and conduct a review of executive compensation. The incumbent Board never followed through. Instead, Mr. Equels selected only one new director without any independent search, Ms. Bryan, who had pre-existing relationship with him. The Board conducted only a cursory, selective, self-affirming compensation review using the same small search firm that recommended Mr. Equels's outrageous compensation package in the first place, with no changes announced. We believe that the incumbent Board does not value stockholder feedback, and this farce of a process demonstrates that.

    The Incumbent Board has No Plan and is Continuing to Mislead Stockholders to Distract from its Failures.

    Mr. Kellner is one of AIM's largest stockholders and has held his shares for several years. Mr. Deutsch is also one of AIM's largest stockholders and has also held his shares for several years. They have no motivations other than to improve the Company's performance. Collectively, the Kellner Group is AIM's largest stockholder according to AIM's proxy statement. If the incumbent Board was acting in good faith, it would be attempting to attract long-term stockholders like Mr. Kellner and Mr. Deutsch. Instead, the incumbent Board has attacked them and questioned their motives with no basis. We believe this behavior alienates potential long-term investors like Mr. Kellner and Mr. Deutsch.

    The incumbent Board's primary argument for its election – suggesting that the Kellner Group includes criminals – is completely and demonstrably false. Likewise, the claim that Mr. Kellner is motivated to pursue these nominations by the potential to recoup expenses is illogical and disingenuous. It is utterly shameless in our view for the incumbent Board, which has squandered $15 to $20 million to thwart the expressed will of stockholders and forced them to foot the bill without giving them any say in the matter, to take issue with the Kellner Group transparently disclosing the intent to seek reimbursement (of a fraction of the amount spent by AIM) in furtherance of the will of stockholders. Given AIM's distressed financial condition, the idea advanced by the incumbent Board that the Kellner Group is motivated by access to AIM's capital is frivolous.

    These are the facts:

    • Each of the Kellner Group Nominees will bring desperately needed skills, experience and credibility to AIM's Board – each of them is an accomplished and respected business person in their field and none of them has any criminal history whatsoever.
    • There are no other AIM stockholders or other third parties involved in the Kellner Group's activities, nor were there any other AIM stockholders or other third parties involved in Mr. Kellner's nominations and solicitation for AIM's 2023 annual meeting of stockholders.

    The AIM Board's tired and pathetic attempt to connect the Kellner Group to Mr. Tudor and Mr. Xirinachs – whose past histories with respect to AIM are well-known at this point – is a misleading distraction from their own fiduciary duty breaches, the plummeting stock price that continues to reach new lows, and complete lack of a plan to change course.

    The Incumbent Board's Breach of Fiduciary Duties, Gross Waste and Lack of Transparency are Disqualifying.

    We believe the Board's breach of its fiduciary duties, gross waste in pursuit of its improper purpose of entrenchment and disenfranchisement and continuing lack of transparency and attempts to mislead stockholders are disqualifying. No Board acting in good faith could justify these actions. But for the incumbent Board, which has overseen a massive destruction in stockholder value and 99+% stock price decline under its control, to engage in this bad faith effort is completely shocking to us.

    Unfortunately, the incumbent Board's failures are far broader than this and include, among others, large and increasing net losses, excessive G&A spending, inadequate R&D spending, excessive executive compensation, a stagnant clinical program that lacks focus and proper investment, financial mismanagement, a failure to attract long-term investment and poor corporate governance practices. The incumbent Board has communicated no plans to change any of this and promises only more of the same, with better outcomes somehow perpetually right around the corner. All of this is discussed in more detail in the Kellner Group's proxy statement and will be highlighted in more detail in subsequent communications to stockholders, along with why the Kellner Group Nominees are the only choice to turn around AIM's fortunes and finally start creating value for stockholders.

    THE KELLNER GROUP URGES ALL STOCKHOLDERS TO VOTE ON THE GOLD PROXY CARD TODAY TO ELECT TED D. KELLNER, TODD DEUTSCH, ROBERT L. CHIOINI AND PAUL SWEENEY

    Contact:

    Okapi Partners LLC

    1212 Avenue of the Americas, 17th Floor,

    New York, New York 10036

    Stockholders may call toll-free: (844) 343-2621

    Banks and brokers call: (212) 297-0720

    Email: [email protected]

    Important Information and Participants in the Solicitation

    The Kellner Group has filed a definitive proxy statement and associated GOLD proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for the election of its slate of highly qualified director nominees at the upcoming annual meeting of stockholders of AIM. Details regarding the Kellner Group Nominees are included in its proxy statement.

    THE KELLNER GROUP STRONGLY ADVISES ALL STOCKHOLDERS OF AIM TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

    Information regarding the identity of participants in the Kellner Group's solicitation, and their direct or indirect interests, by security holdings or otherwise, is set forth in the Kellner Group's proxy statement. Stockholders can obtain a copy of the proxy statement, and any amendments or supplements thereto and other documents filed by the Kellner Group with the SEC for no charge at the SEC's website at www.sec.gov. Copies will also be available at no charge at the following website: https://www.okapivote.com/AIM. Investors can also contact Okapi Partners LLC at the telephone number or email address set for the above.

    SOURCE Kellner Group

    Get the next $AIM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What did the Delaware Supreme Court rule regarding the AIM Board's actions?

      The Delaware Supreme Court ruled that the AIM Board breached its fiduciary duties by adopting bylaws with improper motives aimed at maintaining control and interfering with Kellner's nomination notice.

    • How much money has the AIM Board reportedly wasted, according to the Kellner Group?

      The Kellner Group argues that the AIM Board has wasted between $15 million to $20 million over the last two years due to improper actions, instead of focusing on the company's research and development.

    • What issues is the incumbent AIM Board facing in terms of stockholder trust and financial performance?

      The incumbent AIM Board is accused of misleading stockholders and failing to communicate a genuine plan to improve financial performance, resulting in a stock price decline of over 99%.

    • What qualifications do the Kellner Group nominees have that could benefit AIM?

      The Kellner Group nominees bring necessary skills, experience, and credibility that are seen as essential for turning around AIM's performance and creating value for stockholders.

    • What action does the Kellner Group encourage stockholders to take regarding upcoming board elections?

      The Kellner Group urges stockholders to vote for its nominees using the GOLD proxy card to ensure accountability in AIM's board and to initiate necessary changes for the company's success.

    Recent Analyst Ratings for
    $AIM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIM
    SEC Filings

    View All

    SEC Form 10-Q filed by AIM ImmunoTech Inc.

    10-Q - AIM ImmunoTech Inc. (0000946644) (Filer)

    8/14/25 4:15:52 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - AIM ImmunoTech Inc. (0000946644) (Filer)

    7/31/25 4:45:56 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by AIM ImmunoTech Inc.

    424B5 - AIM ImmunoTech Inc. (0000946644) (Filer)

    7/30/25 6:30:43 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

    Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-growing therapeutic area OCALA, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has issued a patent covering the Company's proprietary use of Ampligen® (Rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. "We remain committed to strengthening our global intellectual property protecti

    9/25/25 8:45:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

    OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published a new peer-reviewed article providing evidence of a positive combination effect of AIM's drug Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The paper concluded that the ability of systemic chemokine modulation to eliminate the PD-1-resistance of cold tumors indicates that intratumoral cytotoxic t-lymphocyte accumulation, rather than tumor immunogenicity, is the key factor limiting the therapeutic effectiveness of immune checkpoint inhibitors. These data suggest a broad the

    9/22/25 9:00:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

    Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program OCALA, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the presentation on the latest positive progress from its Ampligen clinical program in pancreatic cancer at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research

    9/4/25 11:00:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kellner Ted D

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    7/21/25 4:10:22 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:16 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:19 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group resumed coverage on AIM ImmunoTech with a new price target

    Maxim Group resumed coverage of AIM ImmunoTech with a rating of Buy and set a new price target of $2.00

    2/9/21 4:10:39 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:16 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mitchell William M bought $5,000 worth of shares (196,851 units at $0.03), increasing direct ownership by 61% to 521,723 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:19 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO & President Equels Thomas K bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 104% to 3,867,533 units (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    4/23/25 4:35:17 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Financials

    Live finance-specific insights

    View All

    AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer) Company to host conference call and webcast on Tuesday, April 1st at 8:30 AM ET OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported its financial results for the fourth quarter and full year 2024 and provided a business

    3/27/25 8:05:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    – Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu

    11/15/24 7:29:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

    OCALA, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q3 2024 operational and financial results on Friday, November 15, 2024 at 8:30 AM ET. The call will be hosted by members of AIM's leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Invest

    11/6/24 9:00:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Leadership Updates

    Live Leadership Updates

    View All

    AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

    OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Company's Board of Directors (the "Board") has, by unanimous vote, appointed David Chemerow as an Independent Director to the Board, effective immediately. Mr. Chemerow brings more than 40 years of finance, accounting and operations leadership experience across multiple industries. He previously served as the Chief Financial Officer and Treasurer, and prior to that as Chief Revenue Officer, of Comscore, Inc., an American-based global media measurement and analytics company. Prior to his tenure at Comscore, Mr. Chemerow served as the Chief Operating Officer an

    2/26/25 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members

    Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Amo

    12/12/24 3:00:00 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kellner Group Announces Support from Another Former AIM Senior Executive

    Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we" or "us" and, as nominees, t

    12/12/24 8:16:14 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by AIM ImmunoTech Inc.

    SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)

    11/14/24 3:21:36 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    9/11/24 5:40:58 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care